AC133 expression in human stem cells

Bhatia, M
November 2001
Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1685
Academic Journal
journal article
Expression of cell surface markers on human hematopoietic cells has provided a method for characterizing subsets of cells with distinct biological functions. This is largely due to the ability to separate highly purified subpopulations of cells for comparative analysis. Relationships between the cell surface phenotype of these subpopulations and their proliferative and differentiative capacity have been instrumental in defining the hierarchical organization of cells comprising the human hematopoietic system. The identification and isolation of human hematopoietic cells expressing AC133, combined with use of in vitro and in vivo assays, has provided novel insights into the hematopoietic progenitor and stem cell compartment in the human. More recent studies have offered evidence that AC133 expression is not limited to primitive blood cells, but also defines unique cell populations in non-hematopoietic tissues. These findings will be reviewed here in the context of human hematopoiesis and the potential role and utility of AC133 expression in the human.


Related Articles

  • Spotlight on hematopoietic stem cells: looking beyond dogma. Introduction. Nolta, J A; Jordan, C T // Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1677 

    No abstract available.

  • CD34+, kit+, rhodamine123low phenotype identifies a marrow cell population highly enriched for human hematopoietic stem cells. Ratajczak, M Z; Pletcher, C H; Marlicz, W; Machalinski, B; Moore, J; Wasik, M; Ratajczak, J; Gewirtz, A M // Leukemia (08876924);Jun98, Vol. 12 Issue 6, p942 

    We hypothesized that human hematopoietic cells displaying a CD34[SUP+], kit[SUP+], rhodamine123[SUPlow] phenotype would be highly enriched for cells with stem-like properties. To test this hypothesis, we employed fluorescence activated cell sorting (FACS) to isolate cells with this phenotype...

  • Van Bekkum Award.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS1 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S1. DOI: 10.1038/sj/bmt/1703429

  • Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT. Bosch-Vizcaya, A; Rodriguez-Romanos, R; Nieto, J B; de la Cámara, R; Brunet, S; Vallejo, C; Osca-Gelis, G; Martínez-Laperche, C; Buño, I; Urbano-Ispizúa, Á; González, M; Jiménez-Velasco, A; Gallardo, D // Bone Marrow Transplantation;Feb2015, Vol. 50 Issue 2, p298 

    The article discusses research which retrospectively examines patient-donor pairs to determine the impact of mismatching for UTA2-1 immunogenic peptide on clinical outcome after allo hematopoietic stem cell transplantation (allo-HSCT) from an HLA-identical sibling donor. It reveals the aspect of...

  • Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Mikkola, Hanna K. A.; Klintman, Jenny; Yang, Haidi; Hock, Hanno; Schlaeger, Thorsten M.; Fujiwara, Yuko; Orkin, Stuart H. // Nature;1/30/2003, Vol. 421 Issue 6922, p547 

    The production of blood cells is sustained throughout the lifetime of an individual by haematopoietic stem cells (HSCs). Specification of HSCs from mesoderm during embryonic development requires the stem cell leukaemia SCL/tal-1 gene product. Forced expression of SCL/tal-1 strongly induces blood...

  • CD34+ or CD34-: which is the more primitive? Engelhardt, M.; Lubbert, M.; Guo, Y. // Leukemia (08876924);Sep2002, Vol. 16 Issue 9, p1603 

    Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC). HSC represent a very small subset of hematopoietic cells and provide self-renewal, possess differentiation capacity and allow a constant supply of the entire hematopoietic...

  • Hematopoietic differentiation of umbilical cord blood-derived very small embryonic/epiblast-like stem cells. Ratajczak, J.; Zuba-Surma, E.; Klich, I.; Liu, R.; Wysoczynski, M.; Greco, N.; Kucia, M.; Laughlin, M. J.; Ratajczak, M. Z. // Leukemia (08876924);Aug2011, Vol. 25 Issue 8, p1278 

    A population of CD133(+)Lin(-)CD45(-) very small embryonic/epiblast-like stem cells (VSELs) has been purified by multiparameter sorting from umbilical cord blood (UCB). To speed up isolation of these cells, we employed anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor...

  • Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Zong, Y.; Zhou, S.; Sorrentino, B. P. // Leukemia (08876924);Sep2005, Vol. 19 Issue 9, p1590 

    Selective inhibition of the BCR/ABL tyrosine kinase by imatinib has become a first-line therapy for chronic myelogenous leukemia (CML). However, BCR/ABL-positive progenitors often persist despite treatment, and relapse associated with resistance to imatinib has been described in many patients...

  • Acute monoblastic leukemia (aleukemic leukemia) presenting as gingival enlargement. Kajale, Manasi M.; Umarji, Hemant R.; Kadam, Sonali; Ranna, Vinisha // International Journal of Students' Research;2014, Vol. 4 Issue 1, p18 

    Acute myeloid leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic stem cells fail to differentiate. Overproliferation of these abnormal cells results in suppression of the normal components of the bone marrow. Aleukemic leukemia is a type of leukemia in which abnormal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics